- Protects against invasive meningococcal infections (primarily serogroups A, C, W and Y)
- Supplementary vaccination for infants and adolescents – catch-up vaccination possible up to the age of 20
- Recommended for people at increased risk or with increased exposure; a booster dose is recommended every 5 years if the risk persists
Meningococcal vaccination is recommended as a supplementary vaccination for infants and adolescents. Catch-up vaccination is possible up to the age of 20 (1 dose of Menquadfi).
In addition, the vaccination is recommended for people who, for medical reasons, are at increased risk of invasive infection or are exposed to an increased risk of exposure. If the risk remains constant, a booster vaccination is recommended for these groups every 5 years.
An increased risk of exposure exists, for example, for:
• Laboratory staff working with meningococci
• Individuals following close contact with a case of invasive meningococcal disease (IMD) of serogroups A, C, W or Y (post-exposure prophylaxis)
• Recruits
• Travellers to endemic areas (duration of travel > 1 month) or epidemic areas (even for short stays)
• Depending on the season, also for travellers at risk, particularly for serogroups A, C, W and Y
Since 2022, vaccination against meningococcal serogroup B (4CMenB vaccine, Bexsero®) has also been recommended for these indications (bookable separately) – with the exception of contacts of a single MenB IME case (no effect on colonisation) and travel indications
Book an Appointment